sonesitatug vedotin

News

AstraZeneca has served up a robust set of interim results, leavened by strong sales of cancer drugs, but with some mixed pipeline news on the side.

News

MSD has signed a license agreement for a KRAS G12D inhibitor from China's SciBrunch, paying $400m upfront for the preclinical candidate.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.